Literature DB >> 15003318

An absence of CCR5 on donor cells results in acceleration of acute graft-vs-host disease.

Lisbeth A Welniak1, Zhao Wang, Kai Sun, William Kuziel, Miriam R Anver, Bruce R Blazar, William J Murphy.   

Abstract

OBJECTIVE: Chemokines have been postulated to play a role in the pathogenesis of graft-vs-host disease (GVHD) after allogeneic hematopoietic transplantation. Recent reports have indicated that the absence of donor expression of CCR5 on T cells ameliorates GVHD in models using no conditioning of the recipient. We therefore assessed the role of CCR5 on donor cells in models where intensive conditioning of the recipient occurs, thus more appropriately mirroring the clinical experience.
METHODS: Lethally irradiated mice received allogeneic bone marrow transplants. Recipients were given full MHC-mismatched donor bone marrow and splenocytes from CCR5 knockout (KO) mice vs wild-type (WT) control donors.
RESULTS: Recipients of CCR5 KO donor cells succumbed to acute GVHD at an accelerated rate compared to mice receiving WT cells. Donor CD8+ T cells expanded to a significantly greater extent in recipients of CCR5 KO vs WT control cells. T cells recovered from recipients of CCR5 KO cells produced more IFN-gamma and TNF-alpha and proliferated to a T-cell mitogen at a significantly greater level then T cells from recipients of WT cells, indicating that CCR5 plays a role in downregulating donor alloreactive CD8+ T-cell expansion. Histological assessment of the mice indicated pathological lesions in the kidneys and a greater degree of liver pathological changes in mice that received CCR5 KO donor grafts.
CONCLUSIONS: These results indicate that the role of CCR5 in allogeneic bone marrow transplants and GVHD is more complex than initially thought. In a murine transplant model with intensive conditioning, the overall effect of absent CCR5 expression on donor cells results in greater GVHD and donor T-cell expansion.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15003318     DOI: 10.1016/j.exphem.2003.12.003

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  26 in total

Review 1.  Biology-driven developments in the therapy of acute graft-versus-host disease.

Authors:  Robert Zeiser
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  Critical role for CCR5 in the function of donor CD4+CD25+ regulatory T cells during acute graft-versus-host disease.

Authors:  Christian A Wysocki; Qi Jiang; Angela Panoskaltsis-Mortari; Patricia A Taylor; Karen P McKinnon; Lishan Su; Bruce R Blazar; Jonathan S Serody
Journal:  Blood       Date:  2005-07-07       Impact factor: 22.113

Review 3.  Bone marrow transplantation and approaches to avoid graft-versus-host disease (GVHD).

Authors:  Bruce R Blazar; William J Murphy
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-09-29       Impact factor: 6.237

4.  Secondary lymphoid organs contribute to, but are not required for the induction of graft-versus-host responses following allogeneic bone marrow transplantation: a shifting paradigm for T cell allo-activation.

Authors:  Ines A Silva; Krystyna Olkiewicz; David Askew; Jacquelyn M Fisher; Meghana N Chaudhary; Kevin M Vannella; Daphne T Deurloo; Sung W Choi; Elizabeth M Pierce; Shawn G Clouthier; Chen Liu; Kenneth R Cooke
Journal:  Biol Blood Marrow Transplant       Date:  2010-02-01       Impact factor: 5.742

5.  Peyer patches are not required for acute graft-versus-host disease after myeloablative conditioning and murine allogeneic bone marrow transplantation.

Authors:  Lisbeth A Welniak; Dmitry V Kuprash; Alexei V Tumanov; Angela Panoskaltsis-Mortari; Bruce R Blazar; Kai Sun; Sergei A Nedospasov; William J Murphy
Journal:  Blood       Date:  2005-09-13       Impact factor: 22.113

6.  In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity.

Authors:  Ryosei Nishimura; Jeanette Baker; Andreas Beilhack; Robert Zeiser; Janelle A Olson; Emanuela I Sega; Mobin Karimi; Robert S Negrin
Journal:  Blood       Date:  2008-06-18       Impact factor: 22.113

7.  Preventive usage of broad spectrum chemokine inhibitor NR58-3.14.3 reduces the severity of pulmonary and hepatic graft-versus-host disease.

Authors:  Sandra Miklos; Gunnar Mueller; Yayi Chang; Abdellatif Bouazzaoui; Elena Spacenko; Thomas E O Schubert; David J Grainger; Ernst Holler; Reinhard Andreesen; Gerhard C Hildebrandt
Journal:  Int J Hematol       Date:  2009-03-14       Impact factor: 2.490

8.  Reciprocal function of Galphai2 and Galphai3 in graft-versus-host disease.

Authors:  Yong Zhu Jin; Brian D Thompson; Zho Yan Zhou; Yineng Fu; Lutz Birnbaumer; Mei X Wu
Journal:  Eur J Immunol       Date:  2008-07       Impact factor: 5.532

9.  CCR5 blockade combined with cyclosporine A attenuates liver GVHD by impairing T cells function.

Authors:  Bo Tang; Hanyun Ren; Huihui Liu; Yongjin Shi; Wei Liu; Yujun Dong; Yue Yin; Shengchao Miao
Journal:  Inflamm Res       Date:  2016-07-16       Impact factor: 4.575

10.  CCR5 and CXCR3 are dispensable for liver infiltration, but CCR5 protects against virus-induced T-cell-mediated hepatic steatosis.

Authors:  P J Holst; C Orskov; K Qvortrup; J P Christensen; A R Thomsen
Journal:  J Virol       Date:  2007-07-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.